Meiji seika pharma announces investment in arcalis, inc.

Tokyo--(business wire)---- $arct #clinicaltrial--meiji seika pharma co., ltd. (headquarters: tokyo, japan, president and representative director: daikichiro kobayashi; hereinafter referred to as "meiji seika pharma") today announced its investment in arcalis, inc. (headquarters: minami-soma city, fukushima prefecture; president: satoshi takamatsu; hereinafter referred to as "arcalis"). arcalis is a joint venture between axcelead, inc., which manages a group of world-class pharmaceutical and healthcare platform companie.
ARCT Ratings Summary
ARCT Quant Ranking